Ciara Kennedy, Amplyx CEO
Amplyx touts upbeat readout from a small PhII study for lead antifungal
Amplyx, a biotech focused on treating patients with compromised immune systems, is touting its lead program following a Phase II study.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
